Company Overview

Established in August 1988, Washington Biotechnology, Inc. (WBI) is located in Baltimore, Maryland, USA.

WBI’s major service areas are:

• In Vivo Efficacy Testing of compounds and biologics over a wide range of disease models including inflammatory/autoimmune diseases and cancer.
• Vaccine testing services including vaccine efficacy testing in disease model studies such as arthritis.
• Bacterial efficacy studies in mice and rats to determine antibiotic efficacy.
• Support Services including Pharmacokinetics, Toxicity, Pain Studies and Necropsy.

 

Registration and Accreditation:

U.S. Department of Agriculture (USDA)  Registration No. 51-R-031

Office for Laboratory Animal Welfare (OLAW) Animal Welfare Assurance Statement A4192-01

AAALAC accredited

Leadership

Sean O'Neill, PhD, MBA
Founder, President and Director of Operations

Dr. O'Neill is the Founder, President and Director of Operations for Washington Biotechnology, Inc.

Prior to founding WBI, Dr. O'Neill was Vice President of Immunodiagnostics for Pharmacia Diagnostics, Columbia, MD. Previous positions held with Electro-Nucleonics/ Pharmacia Diagnostics included Director of Product Development, Director of Manufacturing and Research & Development, and General Manager of Immunodiagnostics. Dr. O'Neill led the development and licensing of major diagnostic tests for AIDS and hepatitis and has over 100 publications in enzyme catalysis, immunology and immunodiagnostics.

Dr. O'Neill holds a PhD in Chemistry from the University of Toronto and an MBA from the American University, Washington D.C.